Spire Healthcare Group PLC - London-based healthcare company - Says it is ‘pleased to confirm that performance in the period has been in line with our expectations and the 2025 guidance provided’. Adds that its ‘on-going transformation programme’ remains on track with the benefits seen as weighted towards the second half of 2025. Says it expects the programme to deliver ‘at least’ £30 million in ‘efficiencies’ this year. Furthermore, Spire confirms that due to having 100% direct UK revenue exposure, it does not currently expect recent tariff announcements to cause any material cost or supply chain impacts. Finally, Spire says it was recently named a founding supplier as part of the UK government’s National Strategic Supplier Relationship programme, adding: ‘We look forward to working with the NHS to build a strong, long term and sustainable footing for increased NHS commissioning.’
Current stock price: 197.60 pence, up 1.1% in London on Wednesday
12-month change: down 24%
Copyright 2025 Alliance News Ltd. All Rights Reserved.